FilingPulse

GOVX insider transaction filings

GeoVax Labs, Inc. — 43 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-22. Screen GOVX transaction legs live →

Insider transaction summary — last 90 days

No Form 4 filings for GOVX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.

Recent Form 4 filings — GeoVax Labs, Inc.

FiledFormInsiderReported transactionsSource
2026-06-224Morgan Jayne — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2026-06-224Lemerond Nicole — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2026-06-224McKee Kelly T. Jr. — Chief Medical OfficerGrant/award (A): 17,600 (derivative) @ $0EDGAR
2026-06-224Sharkey John W. — VP, Business DevelopmentGrant/award (A): 17,600 (derivative) @ $0EDGAR
2026-06-224Kollintzas Dean G — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2026-06-224Reynolds Mark — CFOGrant/award (A): 17,600 (derivative) @ $0EDGAR
2026-06-224SPENCER JOHN N JR — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2026-06-224NEWMAN MARK J — Chief Scientific OfficerGrant/award (A): 17,600 (derivative) @ $0EDGAR
2026-06-224DODD DAVID A — President, CEO, DirectorGrant/award (A): 29,300 (derivative) @ $0EDGAR
2026-06-224CHASE RANDAL D — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2026-06-224MCNALLY ROBERT T — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2025-10-204SPENCER JOHN N JR — DirectorPurchase (P): 10,000 @ $0.55EDGAR
2025-08-084McKee Kelly T. Jr. — Chief Medical OfficerPurchase (P): 1,107 @ $0.67EDGAR
2025-06-064Morgan Jayne — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2025-06-064Lemerond Nicole — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2025-06-064McKee Kelly T. Jr. — Chief Medical OfficerGrant/award (A): 70,000 (derivative) @ $0EDGAR
2025-06-064Sharkey John W. — VP, Business DevelopmentGrant/award (A): 70,000 (derivative) @ $0EDGAR
2025-06-064Kollintzas Dean G — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2025-06-064Reynolds Mark — CFOGrant/award (A): 70,000 (derivative) @ $0EDGAR
2025-06-064SPENCER JOHN N JR — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2025-06-064NEWMAN MARK J — Chief Scientific OfficerGrant/award (A): 70,000 (derivative) @ $0EDGAR
2025-06-064DODD DAVID A — President, CEO, DirectorGrant/award (A): 185,500 (derivative) @ $0EDGAR
2025-06-064CHASE RANDAL D — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2025-06-064MCNALLY ROBERT T — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2025-04-114SPENCER JOHN N JR — DirectorPurchase (P): 10,000 @ $0.98EDGAR
2025-04-104Sharkey John W. — VP, Business DevelopmentPurchase (P): 6,000 @ $0.99EDGAR
2025-04-014DODD DAVID A — President, CEO, DirectorPurchase (P): 10,000 @ $1.08EDGAR
2025-03-314Reynolds Mark — CFOPurchase (P): 6,800 @ $1.08EDGAR
2024-08-144Morgan Jayne — DirectorGrant/award (A): 8,050 (derivative) @ $0EDGAR
2024-08-144Lemerond Nicole — DirectorGrant/award (A): 8,050 (derivative) @ $0EDGAR
2024-08-144McKee Kelly T. Jr. — Chief Medical OfficerGrant/award (A): 15,700 (derivative) @ $0EDGAR
2024-08-144Sharkey John W. — VP, Business DevelopmentGrant/award (A): 15,700 (derivative) @ $0EDGAR
2024-08-144Kollintzas Dean G — DirectorGrant/award (A): 8,050 (derivative) @ $0EDGAR
2024-08-144Reynolds Mark — CFOGrant/award (A): 15,700 (derivative) @ $0EDGAR
2024-08-144SPENCER JOHN N JR — DirectorGrant/award (A): 8,050 (derivative) @ $0EDGAR
2024-08-144NEWMAN MARK J — Chief Scientific OfficerGrant/award (A): 15,700 (derivative) @ $0EDGAR
2024-08-144DODD DAVID A — President, CEO, DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2024-08-144CHASE RANDAL D — DirectorGrant/award (A): 8,050 (derivative) @ $0EDGAR
2024-08-144MCNALLY ROBERT T — DirectorGrant/award (A): 8,050 (derivative) @ $0EDGAR
2024-08-124DODD DAVID A — President, CEO, DirectorPurchase (P): 8,000 @ $1.95EDGAR
2024-02-224DODD DAVID A — President, CEO, DirectorPurchase (P): 520 @ $2.15 · Purchase (P): 8,209 @ $2.27EDGAR
2024-02-074Reynolds Mark — CFOPurchase (P): 2,000 @ $2.77EDGAR
2023-12-264McKee Kelly T. Jr. — Chief Medical OfficerPurchase (P): 6,944 @ $0.36EDGAR

Recent 8-K events — GeoVax Labs, Inc.

FiledFormItems reportedSource
2026-09-108-K8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2026-08-288-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits		EDGAR
2026-08-288-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
9.01 — Financial Statements and Exhibits		EDGAR
2026-07-278-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-07-108-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-06-178-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-198-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits		EDGAR
2026-05-148-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-05-078-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits		EDGAR
2026-04-158-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=GOVX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →